JP2016505039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505039A5 JP2016505039A5 JP2015553775A JP2015553775A JP2016505039A5 JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5 JP 2015553775 A JP2015553775 A JP 2015553775A JP 2015553775 A JP2015553775 A JP 2015553775A JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- metformin
- glp1r agonist
- glp1r
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| US61/753,567 | 2013-01-17 | ||
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505039A JP2016505039A (ja) | 2016-02-18 |
| JP2016505039A5 true JP2016505039A5 (cg-RX-API-DMAC10.html) | 2017-02-16 |
| JP6445459B2 JP6445459B2 (ja) | 2018-12-26 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553775A Active JP6445459B2 (ja) | 2013-01-17 | 2014-01-14 | Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用 |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
| WO2019217165A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
| EP4130005A4 (en) * | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| CN115315426B (zh) * | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| US12582651B2 (en) * | 2020-12-31 | 2026-03-24 | Dong Kook Pharm. Co., Ltd. | Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate |
| JP2025532651A (ja) | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| US20260199503A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| AU2006311601A1 (en) * | 2005-11-07 | 2007-05-18 | Elixir Pharmaceuticals, Inc. | Combinations of metformin and meglitinide |
| EA018225B1 (ru) * | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| MX2011010347A (es) * | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| JP5832439B2 (ja) * | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned